Article
Surgery
Ivy H. Gardner, Katherine A. Kelley, Walaa F. Abdelmoaty, Ahmed Sharata, Amanda V. Hayman, Mark H. Whiteford
Summary: This study retrospectively analyzed 44 patients with mid and low rectal cancer who underwent low anterior resection via taTME. The results showed that 91% of TME specimens were graded as complete or near complete, with a post-operative complication rate of 18.2% and a local recurrence rate of 4.5%. This indicates that using the taTME approach can yield comparably safe and effective outcomes to laparoscopic proctectomy in technically complex cases.
SURGICAL ENDOSCOPY AND OTHER INTERVENTIONAL TECHNIQUES
(2022)
Article
Surgery
Jingqing Ren, Shaojie Liu, Huixing Luo, Bailin Wang, Fan Wu
Summary: There was no significant difference in short-term efficacy between TaTME and LaTME for low rectal cancer, but TaTME had a longer operation time and a greater circumferential resection margin distance.
ASIAN JOURNAL OF SURGERY
(2021)
Article
Surgery
Ziwei Zeng, Zhihang Liu, Shuangling Luo, Zhenxing Liang, Liang Huang, Lei Ruan, Junji Chen, Haiqing Jie, Wenfeng Liang, Huashan Liu, Liang Kang
Summary: There were no significant differences in the 3-year local recurrence rate between the taTME and laTME groups. Additionally, the disease-free survival and overall survival rates within 3 years after surgery were also similar between the two groups.
SURGICAL ENDOSCOPY AND OTHER INTERVENTIONAL TECHNIQUES
(2022)
Article
Medicine, General & Internal
Stefano Scabini, Emanuele Romairone, Davide Pertile, Andrea Massobrio, Alessandra Aprile, Luca Tagliafico, Domenico Soriero, Luca Mastracci, Federica Grillo, Almalina Bacigalupo, Ciro Marrone, Maria Caterina Parodi, Marina Sartini, Maria Luisa Cristina, Roberto Murialdo, Gabriele Zoppoli, Alberto Ballestrero
Summary: This study evaluated the results of laparotomic, laparoscopic, and robotic surgery in treating rectal cancer. The study found that laparoscopic TME is a better choice in a multidisciplinary context, while robotic TME has a significant difference in terms of hospital stay.
Article
Medicine, General & Internal
Antonio Caycedo-Marulanda, Lawrence Lee, Sami A. Chadi, Chris P. Verschoor, Jordan Crosina, Shady Ashamalla, Carl J. Brown
Summary: The study found that transanal TME performed by experienced surgeons had a low incidence of local recurrence and systemic recurrence, suggesting it may be an acceptable approach for rectal cancer management.
Article
Oncology
Severin Gloor, Gioia Pozza, Rebekka Troller, Markus Wehrli, Michel Adamina
Summary: A study of 165 patients with distal rectal cancer who underwent taTME found that this procedure is a viable alternative to conventional TME, with high surgical quality and favorable outcomes.
Article
Public, Environmental & Occupational Health
Henry H. Chill, Shani Y. Parnasa, Noam Shussman, Roie Alter, Briggite Helou, Adiel Cohen, Alon J. Pikarsky, David Shveiky
Summary: This study compared urinary dysfunction and its impact on quality of life in women who underwent total mesorectal excision versus partial mesorectal excision for rectal cancer treatment. The results showed no significant difference in urinary dysfunction or its influence on quality of life between the two groups. Prolonged hospital stay was associated with increased risk of urinary dysfunction to some degree, according to multivariate analysis.
Article
Surgery
Vicente Simo, Patricia Tejedor, Luis Miguel Jimenez, Cristina Hernan, Jaime Zorilla, Jorge Arrredondo, Fernando Lapuente, Carlos Pastor
Summary: This study evaluated the mid-term oncological impact of TaTME for treating rectal cancer and showed positive outcomes at 2 years of follow-up. However, there is a lack of evidence in the literature regarding TaTME and oncological outcomes.
SURGICAL ENDOSCOPY AND OTHER INTERVENTIONAL TECHNIQUES
(2021)
Article
Surgery
Patricia Sylla, Mariana Berho, Dana Sands, Alison Ricardo, Antoinette Bonaccorso, Erin Moshier, Elisabeth Hain, Riva Letchinger, John Marks, Mark Whiteford, Elisabeth Mclemore, Justin Maykel, Karim Alavi, Karen Zaghiyan, Sami Chadi, Sherief F. F. Shawki, Scott Steele, Alessio Pigazzi, Matthew Albert, Teresa DeBeche-Adams, Alexandros Polydorides, Steven Wexner
Summary: This study reports the results of a rigorous quality control process in grading total mesorectal excision (TME) specimens during a multicenter prospective phase 2 trial. The study found a 14% rate of major discordance in grading between the site and central reviewers, and 93% of these discordances were resolved through reconciliation. The study recommends the use of central review and reconciliation for quality control in grading TME specimens.
Review
Health Care Sciences & Services
Simona Giuratrabocchetta, Giampaolo Formisano, Adelona Salaj, Enrico Opocher, Luca Ferraro, Francesco Toti, Paolo Pietro Bianchi
Summary: Minimally invasive treatment of rectal cancer with Total Mesorectal Excision is complex and challenging, with robotic surgery offering advantages in dexterity but cost and benefits still need further evaluation.
JOURNAL OF PERSONALIZED MEDICINE
(2021)
Article
Surgery
Sapho Xenia Roodbeen, Antonino Spinelli, Willem A. Bemelman, Francesca Di Candido, Maylis Cardepont, Quentin Denost, Andre D'Hoore, Bert Houben, Joep J. Knol, Beatriz Martin-Perez, Eric Rullier, Dana Sands, Ilana Setton, Katrien Van de Steen, Pieter J. Tanis, Steven D. Wexner, Roel Hompes, Albert M. Wolthuis
Summary: This study aimed to determine the local recurrence (LR) rate and patterns after transanal total mesorectal excision (TaTME) for rectal cancer. The results showed good locoregional control after TaTME in selected cases from tertiary referral centers and did not indicate an inherent oncological risk of the surgical technique.
Article
Medicine, General & Internal
Deborah Schrag, Qian Shi, Martin R. Weiser, Marc J. Gollub, Leonard B. Saltz, Benjamin L. Musher, Joel Goldberg, Tareq Al Baghdadi, Karyn A. Goodman, Robert R. McWilliams, Jeffrey M. Farma, Thomas J. George, Hagen F. Kennecke, Ardaman Shergill, Michael Montemurro, Garth D. Nelson, Brian Colgrove, Vallerie Gordon, Alan P. Venook, Eileen M. O'Reilly, Jeffrey A. Meyerhardt, Amylou C. Dueck, Ethan Basch, George J. Chang, Harvey J. Mamon
Summary: Preoperative FOLFOX chemotherapy is as effective as preoperative chemoradiotherapy for locally advanced rectal cancer eligible for sphincter-sparing surgery.
NEW ENGLAND JOURNAL OF MEDICINE
(2023)
Article
Surgery
Han Beol Jang, Sang-Bum Kang, Hyein Lee, Byung Jo Choi, Sang Chul Lee
Summary: The study found no significant differences in the occurrence of anastomotic leakage and chronic presacral sinus between Transanal Total Mesorectal Excision (taTME) and Laparoscopic TME (lapTME) in rectal cancer patients. Almost one-third of anastomotic leakages developed into chronic presacral sinus.
ASIAN JOURNAL OF SURGERY
(2022)
Article
Surgery
Francesca Di Candido, Michele Carvello, Deborah S. Keller, Elena Vanni, Annalisa Maroli, Isacco Montroni, Roel Hompes, Matteo Sacchi, Marco Montorsi, Antonino Spinelli
Summary: A comparative cost analysis of Transanal Total Mesorectal Excision (taTME) and laparoscopic TME (lapTME) in rectal cancer surgery found that taTME had higher intraoperative costs in terms of supplies compared to lapTME. However, the duration of surgery, short-term outcomes, and hospital resources utilization to manage the postoperative course were comparable between the two procedures.
UPDATES IN SURGERY
(2021)
Article
Gastroenterology & Hepatology
Ziwei Zeng, Zhihang Liu, Liang Huang, Huashan Liu, Haiqing Jie, Shuangling Luo, Xingwei Zhang, Liang Kang
Summary: The study compared the learning curves and outcomes of transanal total mesorectal excision with laparoscopic total mesorectal excision, finding that in different phases of the learning curve, operative time, intraoperative blood loss, and postoperative stay were significantly lower in the transanal group, with similar short-term and histopathologic outcomes between the two groups.
DISEASES OF THE COLON & RECTUM
(2021)
Article
Oncology
T. Yoshino, G. Argiles, E. Oki, E. Martinelli, H. Taniguchi, D. Arnold, Mishima, Y. Li, B. K. Smruti, J. B. Ahn, I. Faud, C. E. Chee, K. -h. Yeh, P. -c. Lin, C. Chua, H. H. Hasbullah, M. A. Lee, A. Sharma, Y. Sun, G. Curigliano, H. Bando, F. Lordick, T. Yamanaka, J. Tabernero, E. Baba, A. Cervantes, A. Ohtsu, S. Peters, C. Ishioka, G. Pentheroudakis
Summary: The ESMO 2020 guidelines for localised colon cancer were adapted to account for ethnic differences in Asian patients during a special virtual meeting convened by ESMO and JSMO in March 2021. These guidelines represent the consensus opinions of experts from various oncological societies in Asia, and the voting was based on scientific evidence.
ANNALS OF ONCOLOGY
(2021)
Article
Oncology
Valentina Gambardella, Pasquale Lombardi, Juan Antonio Carbonell-Asins, Noelia Tarazona, Juan Miguel Cejalvo, Ines Gonzalez-Barrallo, Jorge Martin-Arana, Roberto Tebar-Martinez, Alba Viala, Gema Bruixola, Cristina Hernando, Inma Blasco, Federica Papaccio, Carolina Martinez-Ciarpaglini, Clara Alfaro-Cervello, Enrique Seda-Garcia, Sebastian Blesa, Isabel Chirivella, Josefa Castillo, Jose Vicente Monton-Bueno, Susana Rosello, Marisol Huerta, Alejandro Perez-Fidalgo, Paloma Martin-Martorell, Amelia Insa-Molla, Tania Fleitas, Pilar Rentero-Garrido, Sheila Zuniga-Trejos, Andres Cervantes, Desamparados Roda
Summary: Molecular-matched therapies have significantly improved cancer treatment outcomes, as demonstrated in this study utilizing a customized Next Generation Sequencing panel. The importance of the institutional molecular tumor board in evaluating the results and optimizing therapy selection for improved disease control was highlighted.
BRITISH JOURNAL OF CANCER
(2021)
Article
Oncology
Antoine Italiano, Philippe A. Cassier, Chia-Chi Lin, Tuomo Alanko, Katriina J. Peltola, Anas Gazzah, Her-Shyong Shiah, Emiliano Calvo, Andres Cervantes, Desamparados Roda, Diego Tosi, Bo Gao, Michael Millward, Lydia Warburton, Minna Tanner, Stefan Englert, Stacie Lambert, Apurvasena Parikh, Daniel E. Afar, Gregory Vosganian, Victor Moreno
Summary: This study presents the safety, efficacy, pharmacokinetic, and pharmacodynamic data of budigalimab in head and neck squamous cell carcinoma and non-small cell lung cancer patients. Results showed that the drug's profiles are similar to other PD-1 inhibitors, and development in combination with novel anticancer agents is ongoing. The objective response rates and median progression-free survival varied slightly between the HNSCC and NSCLC cohorts.
CANCER IMMUNOLOGY IMMUNOTHERAPY
(2022)
Article
Oncology
Yolanda Andreu, Paula Martinez, Ana Soto-Rubio, Silvia Fernandez, Carles Bosch, Andres Cervantes
Summary: This study aimed to determine the prevalence of distress and unmet supportive care needs in post-treatment colorectal cancer (CRC) survivors. Findings showed that one in five CRC survivors had clinical distress and 86% expressed at least one unmet need. The risk factors associated with this included lower socioeconomic status, younger age, and a primary treatment that includes more than surgery.
SUPPORTIVE CARE IN CANCER
(2022)
Article
Oncology
Tenna Vesterman Henriksen, Noelia Tarazona, Amanda Frydendahl, Thomas Reinert, Francisco Gimeno-Valiente, Juan Antonio Carbonell-Asins, Shruti Sharma, Derrick Renner, Dina Hafez, Desamparados Roda, Marisol Huerta, Susana Rosello, Anders Husted Madsen, Uffe S. Love, Per Vadgaard Andersen, Ole Thorlacius-Ussing, Lene Hjerrild Iversen, Kare Andersson Gotschalck, Himanshu Sethi, Alexey Aleshin, Andres Cervantes, Claus Lindbjerg Andersen
Summary: The study demonstrates the strong prognostic value of serial postoperative ctDNA analysis in predicting recurrence and assessing tumor growth rate. The novel combination of ctDNA detection and growth rate assessment provides unique opportunities for guiding treatment decisions.
CLINICAL CANCER RESEARCH
(2022)
Article
Oncology
Paula Montero, Martin Perez-Leal, Jose Alejandro Perez-Fidalgo, Celia Sanz, Cristina Estornut, Ines Roger, Javier Milara, Andres Cervantes, Julio Cortijo
Summary: Skin toxicity caused by paclitaxel could be underestimated as the adverse events may appear asymptomatic. This study found that paclitaxel alters gene and protein expression related to skin markers, and impairs the physical, physiological, and biomechanical properties of the skin in gynecological cancer patients. Prophylactic measures should be taken to prevent these subclinical alterations and potential adverse reactions.
News Item
Oncology
C. Montagut, V. Gambardella, M. Cabeza-Segura, T. Fleitas, A. Cervantes
Correction
Oncology
A. Vogel, A. Cervantes, I. Chau, B. Daniele, J. M. Llovet, T. Meyer, J. -C. Nault, U. Neumann, J. Ricke, B. Sangro, P. Schirmacher, C. Verslype, C. J. Zech, D. Arnold, E. Martinelli
ANNALS OF ONCOLOGY
(2022)
Article
Oncology
Fortunato Ciardiello, Davide Ciardiello, Giulia Martini, Stefania Napolitano, Josep Tabernero, Andres Cervantes
Summary: This review summarizes the progress in the clinical management of patients with metastatic colorectal cancer (mCRC) in the era of precision medicine. Molecular stratification, based on the current treatment algorithm, has been a significant step towards implementing more effective therapeutic approaches. Integrating tumor gene alterations with tumor and microenvironment gene and protein expression profiling, host immune competence, and applying dynamic changes to precision medicine-based continuum of care, could lead to the identification of individual prognostic and predictive parameters for choosing the most appropriate therapeutic program for each patient.
CA-A CANCER JOURNAL FOR CLINICIANS
(2022)
Article
Oncology
Enriqueta Felip, Victor Moreno, Daniel Morgensztern, Giuseppe Curigliano, Piotr Rutkowski, Jose Manuel Trigo, Aitana Calvo, Dariusz Kowalski, Diego Cortinovis, Ruth Plummer, Michele Maio, Paolo A. Ascierto, Vladimir Vladimirov, Andres Cervantes, Enrique Zudaire, Anasuya Hazra, Huybrecht T'jollyn, Nibedita Bandyopadhyay, James G. Greger, Edward Attiyeh, Hong Xie, Emiliano Calvo
Summary: This study assessed the safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of cetrelimab in patients with advanced/refractory solid tumors. The results showed that cetrelimab had favorable pharmacokinetic and pharmacodynamic characteristics, as well as clinical activity, in immune-sensitive advanced cancers.
CANCER CHEMOTHERAPY AND PHARMACOLOGY
(2022)
Article
Oncology
Tessa Suzanne van Schooten, Sarah Derks, Elena Jimenez-Marti, Fatima Carneiro, Ceu Figueiredo, Erika Ruiz, Maria Alsina, Cristina Molero, Marcelo Garrido, Arnoldo Riquelme, Carmelo Caballero, Eva Lezcano, Juan Manuel O'Connor, Federico Esteso, Judith Farres, Jose Manuel Mas, Florian Lordick, Jeannette Vogt, Antonella Cardone, Charis Girvalaki, Andres Cervantes, Tania Fleitas
Summary: The LEGACy study is a multi-institutional research project aimed at filling the knowledge gap on gastric cancer in European and Latin American countries. It will generate novel knowledge on tumor biology characteristics by integrating epidemiological, multi-omics, and clinical data, and develop and validate cost-effective clinical decision-making methods.
Article
Health Care Sciences & Services
Federica Papaccio, Manuel Cabeza-Segura, Blanca Garcia-Mico, Noelia Tarazona, Desamparados Roda, Josefa Castillo, Andres Cervantes
Summary: Precision medicine approaches for solid tumors, mainly based on genomics, have shown limited success. Factors such as gene expression, genomic alterations, and the tumor microenvironment can all influence the response, making a genomics-only approach insufficient. However, the implementation of patient-derived organoids shows promise in predicting patient response to drug treatment.
JOURNAL OF PERSONALIZED MEDICINE
(2022)
Article
Gastroenterology & Hepatology
Jorge Sancho-Muriel, Francisco Giner, Hanna Cholewa, Alvaro Garcia-Granero, Susana Rosello, Blas Flor-Lorente, Andres Cervantes, Eduardo Garcia-Granero, Matteo Frasson
Summary: The aim of this study was to evaluate the prognostic value of a novel variable, the percentage of mesorectal infiltration (PMI), in pT3 rectal cancer. The results showed that PMI was significantly associated with oncological outcomes such as local recurrence, overall recurrence, and overall survival. A PMI >60% can be used as a cut-off value for subclassifying pT3 rectal tumors and may impact decision-making in adjuvant treatment and follow-up schedule.
COLORECTAL DISEASE
(2023)
News Item
Oncology
V. Gambardella, F. Gimeno-Valiente, S. Rosello, A. Cervantes
Article
Oncology
Marta Albanell-Fernandez, Sara S. Oltra, Marta Orts-Arroyo, Maider Ibarrola-Villava, Fany Carrasco, Elena Jimenez-Marti, Andres Cervantes, Isabel Castro, Jose Martinez-Lillo, Gloria Ribas
Summary: To overcome limitations of platinum-based chemotherapy, new active metallodrugs based on other transition metals are being researched. Runat-BI, a ruthenium-based compound, showed selectivity for tumoral cells and reduced tumor growth and migration in three cancer cell lines. Its mechanism of action is related to DNA synthesis and it also increases expression of proapoptotic genes. Runat-BI has potential as an anticancer therapy, but further studies are needed to understand its full potential and mechanism of action.